Recount of the recent ravishing startups (see my alliteration attempt there?)
GH Research Closes $125M Series B Financing
GH Research Ireland Ltd, a Dublin, Ireland-based clinical-stage biopharmaceutical company, closed a $125m Series B financing.
The round was co-led by RA Capital and RTW Investments, LP, with participation from existing investor BVF Partners, and new backers.
Founded in 2018, GH Research Ireland develops novel therapies for the management of psychiatric and neurological disorders. The company’s lead product, GH001, is an innovative drug product for 5-MeO-DMT administration via a proprietary inhalation approach.
GH Research Ireland plans to advance GH001 into clinical development in additional psychiatric and neurological disorders beyond Treatment-Resistant Depression. The company also plans to advance GH002, its injectable 5-MeO-DMT product candidate, into clinical development, as well as explore additional drug delivery approaches.
GH Research Closes $125M Series B Financing | FinSMEs
GH Research Ireland Ltd, a Dublin, Ireland-based clinical-stage biopharmaceutical company, closed a $125m Series B financing
Zedsen Closes $12M Series B Funding
Zedsen, a London, UK-based health tech company, raised $12m in Series B funding at a $110m valuation.
The investors include: Joseph R. Grano, former Chairman and CEO of UBS Financial Services Inc; Nasser Kazeminy, Investor, Founder of NJK Holding and Chairman of the Ellis Island Honor Society (EIHS); Tony Rice, Former CEO of Cable and Wireless; Bonnie Mcalveen Hunter, Chairperson of the Red Cross; and Jim Harpel, Investor at Palm Beach Capital.
The company intends to use the funds to continue to expand operations and its business reach.
Led by CEO Daniel Honeywell and Dr. Caroline Hargrove, CTO, Zedsen is a health tech company with non-invasive technology that helps consumers understand their health based on data coming from their bloodstream. The company’s technology unobtrusively gathers key biological signals from the bloodstream using non-invasive sensors. Data gathered leads to hyper-personalised insights about health, fitness and diet, with support and suggestions as unique as each individual user.
Zedsen Closes $12M Series B Funding | FinSMEs
Zedsen, a London, UK-based health tech company, raised $12m in Series B funding at a $110m valuation
Oxford Endovascular Raises $10M in Funding
Oxford Endovascular, a British MedTech company, raised $10m in a series A funding round.
Backers included a £3m investment from new investors Vulpes Investment Management, who joined to lead the round and funds from the Additio Investment Group. Existing investors Oxford Sciences Innovation PLC, Parkwalk Advisors, Perivoli Innovations, Oxford Investment Consultants, the University of Oxford and private individuals also followed on.
The raise will enable the company to complete development work and gain first in-human data through an early feasibility clinical study. This will then be followed by a further fundraise for larger FDA and CE Mark clinical trials to enter various international markets valued at over $1billion.
Led by Mike Karim, CEO, Oxford Endovascular is developing a treatment for brain aneurysms. The company has developed a micro stent called OxiFlow™️, utilising ‘Origami’ engineering, which can be inserted into the brain blood vessels via minimally invasive groin access. It lies across the base of the aneurysm and causes it to shrink and heal.
The company is a spin-out from Oxford University.
Oxford Endovascular Raises $10M in Funding | FinSMEs
Oxford Endovascular, a British MedTech company, raised $10m in a series A funding round
Pai Skincare Raises £6.4M in Series B Funding
Pai, a London, UK-based organic skincare brand, raised £6.4m (€7.5m /$9m) in Series B funding.
The round was led by Famille C Venture, a private investment firm of the Courtin-Clarins family, founder and owner of the Clarins Group. Prisca Courtin-Clarins, Founder and CEO of Famille C Venture, will join the Pai board. CAPInvest, the family office which invested in Pai’s Series A in 2017, stays on as an investor and board member.
The company intends to use the funds to continue to expand West London R&D and manufacturing facilities, expand its business reach worldwide and launch new products via the brand’s ‘Pai Labs’ innovation hub.
Led by Founder Sarah Brown, who is remaining majority shareholder and CEO, Pai is an organic skincare brand whose flagship product is the Bioregenerate Face Oil. The company is Vegan Society, Cruelty-Free International and London Living Wage accredited.
Pai Skincare Raises £6.4M in Series B Funding | FinSMEs
Pai, a London, UK-based organic skincare brand, raised £6.4m (€7.5m /$9m) in Series B funding
Maxwellia Raises £3.2M in Funding
Maxwellia, an Alderley Park, UK-based self-care company, raised £3.2m in funding.
The round was led by Praetura Ventures with participation from the Future Fund, Catapult Ventures, Alderley Park Ventures and Biocity along with individual and angel investors. In conjunction with the funding, Praetura Ventures’ director Dr Andy Round became a non-executive director.
The company intends to use the funds to scale up the manufacture and rollout of its drugs following MHRA approval, invest in marketing and expand its team.
Founded in 2013 by chief executive Anna Maxwell, a pharmacist with over 20 years’ experience, Maxwellia aims to give people access to the treatments they need by converting prescription-only medicines to versions that can be bought in a pharmacy. It already has three applications under assessment with the MHRA, and is currently awaiting approval of its women’s health product following a public consultation.
Maxwellia Raises £3.2M in Funding
Maxwellia, an Alderley Park, UK-based self-care company, raised £3.2m in funding
Tend Secures $125M in Series C Funding
Tend, a NYC- and Nashville-based provider of dentist services, raised an additional $125m in Series C funding.
The round was led by Addition, with participation from existing investors including GV, Juxtapose, Redpoint and Zigg Capital.
The company intends to use the funds to expand their presence nationally, invest in technology and patient experience and launch a suite of comprehensive services and oral care products.
Led by Doug Hudson, Founding CEO, Tend provides dentist locations offering diverse services that include dental exams, Breezy Braces, oral surgery, emergency care and more, as well as a suite of consumer products. After its launch in October 2019, the company has grown to serve more than 20,000 patients and 256 team members across six locations throughout New York City with plans to expand across the U.S. Over the course of 2021, Tend will build out studios across the country, increasing the number of locations from six in New York City in Chelsea, Flatiron, Grand Central, Wall Street, Upper West Side and Williamsburg, to 20, including new market entries in Washington D.C. and Boston.
Tend Secures $125M in Series C Funding | FinSMEs
Tend, a NYC- and Nashville-based provider of dentist services, raised an additional $125m in Series C funding
Icosavax Closes $100M Series B Financing
Icosavax, Inc., a Seattle, WA-based vaccine development company, closed a $100m Series B financing.
The round was led by RA Capital Management with participation from Janus Henderson Investors, Perceptive Advisors, Viking Global Investors, Cormorant Asset Management, Omega Funds, and Surveyor Capital (a Citadel company) and existing investors Qiming Venture Partners USA, Adams Street Partners, Sanofi Ventures, and ND Capital. A previously announced funding from Open Philanthropy was included in this round. In conjunction with the financing, Peter Kolchinsky, Ph.D., founder and Managing Partner of RA Capital Management, will join the company’s Board of Directors.
The company intends to use the proceeds of the financing for the development of its bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine program through initial clinical studies, continued evaluation of its SARS-CoV-2 vaccine candidate, and further expansion of its pipeline of VLP vaccine candidates focused on protecting older adults from life-threatening respiratory diseases.
Led by Adam Simpson, Chief Executive Officer, Icosavax is focused on developing vaccines against infectious diseases that cause severe, life-threatening respiratory illnesses. The company is advancing VLP vaccine candidates against respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and SARS-CoV-2 (COVID-19).
Icosavax Closes $100M Series B Financing | FinSMEs
Icosavax, Inc., a Seattle, WA-based vaccine development company, closed a $100m Series B financing
Ventus Therapeutics Raises $100M in Series B Financing
Ventus Therapeutics, Inc., a Boston, Massachusetts and Montreal, Canada-based biotechnology company utilizing rational structure-based drug design to discover small-molecule medicines for high value and elusive targets, raised $100m in Series B financing.
The round was led by RA Capital Management with participation from a select syndicate including BVF Partners L.P., Casdin Capital, Cormorant Asset Management, Fonds de solidarité FTQ, and Alexandria Venture Investments.
The company intends to use the funds to advance its pipeline of novel medicines to treat diseases in multiple therapeutic areas and expand platform capabilities. Ventus’ most advanced programs are focused on critical targets of the innate immune system.
Led by Marcelo Bigal, M.D., Ph.D., president and CEO, Ventus is a biopharmaceutical company discovering and developing novel small-molecule medicines by pioneering new frontiers in structure-based drug discovery for biologically validated, but elusive, drug targets. Using two platforms – Structural Immunology and ReSOLVE™ – the company is rapidly advancing a pipeline of new medicines to treat autoimmune diseases, inflammatory diseases and cancer. Its most advanced programs are enabled by the Structural Immunology platform, which unlocks rational, structure-based drug discovery for critical targets in innate immune pathways. The ReSOLVE platform reveals novel druggable sites for traditionally undruggable targets, enabling the company to expand its pipeline into oncology and neurology.
Ventus Therapeutics Raises $100M in Series B Financing | FinSMEs
Ventus Therapeutics, Inc., a Boston, Massachusetts and Montreal, Canada-based biotechnology company utilizing rational structure-based drug design to discover small-molecule medicines for high value and elusive targets, raised $100m in Series B financing
Exclusive: Pendulum Therapeutics Swings $54M Series C To Bridge Gap Between Supplements, Prescription Drugs
Pendulum is now backed by a $54 million Series C round of funding, led by Meritech Capital, with participation from existing investors including Sequoia Capital, True Ventures and Khosla Ventures. This new round of funding nearly doubled the company’s previous venture capital raises, bringing its total to $111 million, according to Cutcliffe.
Colleen Cutcliffe, James Bullard and John Eid, all scientists with deep microbiology, biochemistry, computational and clinical expertise, started the San Francisco-based biotechnology company in 2013 to apply evidence-based microbiome science and DNA sequencing to the area of supplements.
In 2020, Pendulum went on the market with its flagship product, Pendulum Glucose Control, a medical probiotic. It is clinically shown to lower blood sugar spikes and reduce A1C, even while taking common diabetes medicines. Clinical trial findings were published last year in BMJ Open Diabetes, a prestigious peer-reviewed journal.
https://news.crunchbase.com/news/exclusive-pendulum-therapeutics-swings-54m-series-c-to-bridge-gap-between-supplements-prescription-drugs/?utm_source=cb_daily&utm_medium=email&utm_campaign=20210406&utm_content=intro&utm_term=contentVolastra Therapeutics Expands Seed Funding to $44M
Volastra Therapeutics, a NYC-based biotechnology company developing novel therapies for the prevention and treatment of metastatic cancer, extended its original $12m seed round to a total of $44m.
New investors Vida Ventures and Catalio Capital Management joined a syndicate that includes Polaris Partners, Droia Ventures, ARCH Venture Partners and Quark Venture.
The company intends to use the funds to further build-out its technology platform.
Co-founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D. and Samuel Bakhoum, M.D., Ph.D., and led by Charles Hugh-Jones, M.D., Chief Executive Officer, Volastra Therapeutics is pioneering novel approaches to halt or prevent cancer metastasis. Its technology platform exploits unique insights into chromosomal instability (CIN) to rapidly identify and validate novel targets to block metastasis.
Volastra Therapeutics Expands Seed Funding to $44M | FinSMEs
Volastra Therapeutics, a NYC-based biotechnology company developing novel therapies for the prevention and treatment of metastatic cancer, extended its original $12m seed round to a total of $44m
Shoreline Biosciences Raises $43M in Financing
Shoreline Biosciences, Inc., a San Diego, CA-based biotechnology company, completed a $43M funding round.
The round was led by Boxer Capital, with participation from BVF Partners L.P., Commodore Capital, Cormorant Capital, and other investors. In connection with the financing, Christopher Fuglesang, Ph.D., J.D. from Boxer Capital, joined the Shoreline Board of Directors.
Co-founded by cell therapy expert Dan Kaufman, M.D., Ph.D., and biotech veterans Steven Holtzman, William Sandborn, M.D. and Kleanthis G. Xanthopoulos, Ph.D., Shoreline Biosciences is developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and Macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases.
The company intends to use the funds to accelerate the advancement of its proprietary iPSC platform focused on developing next generation NK cell and macrophage-cell therapies, while also supporting research efforts to create potent and persistent NK cell-specific Chimeric Antigen Receptors (CARs), switchable CAR-NK cell engagers and macrophage-specific CARs. In addition, Shoreline has entered into a strategic relationship with the Advanced Cell Therapy Laboratory of UC San Diego to secure GMP manufacturing of its cell therapy products.
Shoreline Biosciences Raises $43M in Financing | FinSMEs
Shoreline Biosciences, Inc., a San Diego, CA-based biotechnology company, completed a $43M funding round
Firefly Health Raises $40M in Series B Funding
Firefly Health, a Watertown, Mass.-based virtual-first healthcare company, closed a $40M Series B financing round.
The round was led by Andreessen Horowitz (a16z) with participation from existing investors F-Prime Capital and Oak HC/FT. As part of the deal, a16z General Partner Julie Yoo will join the Firefly Health board.
The company intends to use the funds to expand operations and its business reach.
Led by CEO Fay Rotenberg, and Executive Chairman Jonathan Bush, Firefly Health offers empathy-driven comprehensive care, administered by a clinical team and network of clinical partners, powered by technology built around people. Every patient is assigned a dedicated care team for continuous, evidence-based virtual and in-person coaching and support. The company’s partnership network also includes on-site access to care providers, home care providers, specialty care organizations, such as Dana Farber and Joslin, as well as many specialty partners.
Firefly Health Raises $40M in Series B Funding | FinSMEs
Firefly Health, a Watertown, Mass.-based virtual-first healthcare company, closed a $40M Series B financing round
Vizgen Raises $37M in Series B Financing
Vizgen, a Cambridge, Mass.-based life science company dedicated to advancing human health by visualizing single-cell spatial genomics information, closed a $37m Series B financing.
The round was co-led by Novalis LifeSciences LLC, and current investor Northpond Ventures with participation from new investors Tao Capital Partners, Pura Vida Investments, LLC, and a large U.S. endowment fund, and current investors ARCH Venture Partners and David Walt, Ph.D., Professor at Harvard Medical School, Core Faculty at the Wyss Institute, and co-founder of Vizgen.
The company intends to use the funds to accelerate growth and infrastructure expansion leading up to full commercial launch.
Led by Terry Lo, President and CEO, Vizgen is developing genomic profiling tools that enable researchers to gain new insight into the biological systems that underlie human health and disease with spatial context. The company’s MERSCOPETM platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution.
Vizgen Raises $37M in Series B Financing | FinSMEs
Vizgen, a Cambridge, Mass.-based life science company dedicated to advancing human health by visualizing single-cell spatial genomics information, closed a $37m Series B financing
Gathered Foods Raises $26.35M In B-2 Bridge Funding Round
Gathered Foods, an Austin, Texas-based maker of plant-based seafood, secured $26.35m in a B-2 bridge funding.
Backers included Louis Dreyfus Company (LDC), Unovis Asset Management, Big Idea Ventures, and others.
The company intends to use the funds to ramp up product innovation and increase the number of products on the market, to extend its international retail footprint, beginning in Europe, with further expansion planned for later in 2021.
Led by Christine Mei, CEO, and Chris Kerr, Co-Founder and Executive Chairman, Gathered Foods is the maker of Good Catch plant-based seafood including single-serve, ready-to-eat pouches of Plant-Based Tuna and frozen Plant-Based Fish Burgers, Plant-Based Crab Cakes and Plant-Based Fish Cakes.
Gathered Foods Raises $26.35M In B-2 Bridge Funding Round | FinSMEs
Gathered Foods, an Austin, Texas-based maker of plant-based seafood, secured $26.35m in a B-2 bridge funding
Mission Barns Raises $24M in Series A Funding
Mission Barns, a Berkeley, CA-based cellular agriculture company, raised $24M in Series A funding.
Backers included Lever VC, Gullspang Re:Food, Humboldt Fund, Green Monday Ventures, Enfini Ventures, a European meat company, Blue Ledge Capital, Prithvi Ventures, Joyance Partners, Global Founders Capital, Point Nine Capital, Better Ventures, and Cantos Ventures.
The company intends to use the funds to scale up its cultivated fat technology and build a pilot manufacturing plant in the Bay Area.
Led by CEO Eitan Fischer, Mission Barns is focused on cultivating animal fat—without the animal. Its technology platform enables starting from a handful of pork, poultry, or beef cells and feeding them a plant-based feedstock inside a cultivator. Applications include: bacon, breakfast patties, burgers, nuggets, dumplings, hot dogs, poultry sausages, meatballs, and more.
Mission Barns Raises $24M in Series A Funding | FinSMEs
Mission Barns, a Berkeley, CA-based cellular agriculture company, raised $24M in Series A funding
Exclusive: OnlineMedEd Expands Global Medical Education Following $20M Growth Round
Digital health care learning platform OnlineMedEd brought in $20 million in a growth round to create content for global health care delivery providers.
Lumos Capital Group led the new financing, which gives OnlineMedEd a total of $25.6 million in funding since Jamie Fitch and Dustyn Williams co-founded the Austin-based company in 2014, Fitch told Crunchbase News.
Traditionally focused on students, the company also attracted new users; practicing providers and faculty. Over the past year, OnlineMedEd launched its Crash Course suite of free online video tutorials to more than 30,000 redeployed health care providers helping during the pandemic. In addition, the company transitioned medical school faculty online.
https://news.crunchbase.com/news/exclusive-onlinemeded-expands-global-medical-education-following-20m-growth-round/?utm_source=cb_daily&utm_medium=email&utm_campaign=20210405&utm_content=intro&utm_term=contentCarta Healthcare Raises $17.3M in Series A Funding
Carta Healthcare, a San Francisco, CA-based provider of AI-powered clinical data abstraction technology and services, raised $17.3M in Series A funding.
The round was led by Storm Ventures with participation from AI Digital Innovation Fund (affiliated with Mass General Brigham), CU Health Innovation Fund (affiliated with University of Colorado Anschutz Medical Campus), Asset Management Ventures, Maverick Ventures, Healthy Ventures, Waterline Ventures, Seven Peaks Ventures, Katalyst Ventures, and Atypical Ventures.
The company intends to use the funds to expand the expert clinical and technical team and enable new partnerships.
Led by Matt Hollingsworth, CEO, Carta Healthcare uses artificial intelligence (AI) technology to allow healthcare organizations to collect, analyze, and act upon clinical data. Through natural language processing and machine learning, the company’s technology reduces the labor associated with manual data abstraction processes typically required to curate actionable datasets and fuels data-driven healthcare decisions that improve patient care.
Carta Healthcare Raises $17.3M in Series A Funding
Carta Healthcare, a San Francisco, CA-based provider of AI-powered clinical data abstraction technology and services, raised $17.3M in Series A funding
EHR startup Canvas Medical lands $17M series A and new partnership with Anthem
Electronic health record startup Canvas Medical scored $17 million in series A funding to expand its health plan partnerships and fuel the growth of its value-based care software.
The company, founded in 2015, provides a cloud-based digital health platform for primary care practices as well as accountable care organizations and independent physician associations. Canvas’ EHR capabilities include scheduling, charting, telehealth, e-prescriptions, lab orders, population health analytics and outreach as well as full revenue cycle management workflows, according to the company. The financing was co-led by Inspired Capital and IA Ventures with participation from IronGrey as well as previous investors Upfront Ventures and iSeed.
The company also scored a new partnership with insurance giant Anthem. The two organizations are working together on a technology integration designed to accelerate value-based care nationwide—bringing Anthem’s machine learning insights to providers directly within Canvas workflows.
Designed to help doctors and insurers collaborate on high-quality patient care, Canvas software replaces traditional electronic health records, practice management systems, telehealth tools and myriad bolt-on applications with one unified system, purpose-built for value-based care.
Data scientist Andrew Hines, founder and CEO of Canvas Medical, set out to develop a “human-centered EMR” that would enable better clinical decisions and patient care as well as an achievable work-life balance for clinicians.
EHR startup Canvas Medical lands $17M series A and new partnership with Anthem | FierceHealthcare
Electronic health record startup Canvas Medical scored $17 million in series A funding to fuel the growth of its value-based care software. The company also scored a new partnership with insurance giant Anthem to integrate the insurer’s machine learning insights into its EHR platform.
Memic Innovative Surgery Closes $96M Series D Financing
Memic Innovative Surgery, a Tel Aviv, Israel-based medical device company dedicated to transforming robot-assisted surgery with its proprietary technology, closed a $96m Series D financing.
The round was led by Peregrine Ventures and Ceros with participation from OurCrowd and Accelmed.
The company intends to use the funds to commercialize the Hominis® robotic-assisted surgical platform in the U.S. and potentially in other countries around the world and expand marketing and sales efforts outside the U.S. The financing will also support continued research and development efforts including expanding Memic Innovative Surgery’s portfolio of products and manufacturing scaleup, as well as provide customer support and training.
Led by Dvir Cohen, co-founder and CEO, Memic is dedicated to advancing the Hominis system, which received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) in February 2021 for use in single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures including benign hysterectomy. The FDA-authorized surgical robotic platform features miniature humanoid-shaped robotic arms that provide human level dexterity, multi-planar flexibility and 360 degrees of articulation. The biomimetic instruments are designed to replicate the motions and capabilities of a surgeon’s arms, with shoulder, elbow and wrist joints. Multiple instruments can be introduced to the body through a single portal and the 360-degree articulation offers obstacle avoidance as well as optimal access and working angles.
Memic Innovative Surgery Closes $96M Series D Financing | FinSMEs
Memic Innovative Surgery, a Tel Aviv, Israel-based medical device company dedicated to transforming robot-assisted surgery with its proprietary technology, closed a $96m Series D financing
Nucleix Secures $55M in Funding
Nucleix, a Rehovot, Israel- and San Diego, CA-based liquid biopsy company, secured $55m in funding.
The round was led by RA Capital Management, with participation from new investors including funds and accounts managed by BlackRock, Lilly Asia Ventures, LYFE Capital and MILFAM. Existing investors participating in the round include OrbiMed, Aurum Ventures, DSC Investment, OCI Bio Investments and Zohar Zisapel.
The company will use the funds to continue the rapid advancement of its methylation technology and to develop its lead product for the early detection of lung cancer.
Led by Chris Hibberd, chief executive officer, Nucleix has developed technology for the detection of methylation changes and is compatible with both next-generation sequencing (NGS) and polymerase chain reaction (PCR) platforms. The company is applying the NGS application of EpiCheck for deep discovery, to reveal new biomarkers that may be used in the early detection and monitoring of cancer. In turn, these discoveries can be advanced as tests using the PCR application of EpiCheck, with the potential to run cost-effectively in both centralized and local laboratories.
Nucleix Secures $55M in Funding | FinSMEs
Nucleix, a Rehovot, Israel- and San Diego, CA-based liquid biopsy company, secured $55m in funding
Microsoft Acquires Health Care AI Company Nuance for $19.7 Billion
Microsoft is acquiring Nuance, a health care AI company in a multi-billion dollar acquisition announced Monday. The American technology giant’s big bet on the conversational AI company is the second-largest since it scooped up LinkedIn for $26.2 billion in 2016.
Nuance is considered a conversational AI pioneer, for its revolutionary technology that helps automate documentation of patient records gathered from the exam room discussions to electronic medical record systems. Nuance’s technology and products are used in over 70 percent of U.S hospitals, according to the company.
Microsoft Acquires Health Care AI Company Nuance for $19.7 Billion
Microsoft Nuance acquisition: Microsoft is betting big on a conversational health care AI company by acquired Nuance for around $20 bn on Monday.
London-based HealthHero acquires Paris’s Qare to dominate the growing European telehealth sector
London-based HealthHero, a healthtech company that offers a suite of virtual healthcare services via phone, video calls, and online chat, has announced the acquisition of Paris-based medical video consultation firm Qare.
The financials of the deal were not disclosed.
The company was founded in 2016 by Alexandre Brel, Augustin Chatenet, and David Lescure. Qare is a platform that provides medical video consultation services. The company’s mission is to transform access to healthcare in France by combining medical expertise with digital innovation.
The practitioners available on Qare are continuously trained in teleconsultation. They practice in France and are all registered with the Council of the Order of Physicians.
